TISIDB

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform IIC4: Cytoplasm ; SUBCELLULAR LOCATION: Isoform IIC3: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform IIC2: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform IIC1: Cell membrane; Single-pass type I membrane protein.
Domain	PF13895 Immunoglobulin domain
Function	Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.

> Gene Ontology [ TOP ]
Biological Process	-
Molecular Function	GO:0019864 IgG binding GO:0019865 immunoglobulin binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04145 Phagosome hsa04380 Osteoclast differentiation
Reactome	-

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FCGR2C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FCGR2C and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27742794	Renal Cell Carcinoma	Promote immunity	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Fc-gamma receptors (FCGRs) are expressed on immune cells, bind to antibodies, and trigger antibody-induced cell-mediated antitumor responses when tumor-reactive antibodies are present. The affinity of the FCGR/antibody interaction is variable and dependent upon FCGR polymorphisms. When higher-affinity genotypes for FCGR2A, FCGR3A, and FCGR2C were considered together, they were associated with significantly increased tumor shrinkage and prolonged survival in response to HD-IL2.

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FCGR2C in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FCGR2C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.796	0.0969
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.511	0.773
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	1.016	0.389
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.292	0.609
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.678	0.681
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.21	0.931
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.022	0.966
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.088	0.956
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.043	0.981
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.827	0.28
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	4.25	0.0395
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.185	0.368

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FCGR2C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCGR2C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCGR2C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCGR2C. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCGR2C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FCGR2C expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FCGR2C and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FCGR2C
Name	Fc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)
Aliases	hFcRII-C; CD32C; Fc fragment of IgG, low affinity IIc, receptor for (CD32); FCRIIC; Fc gamma receptor IIC; I ......
Chromosomal Location	1q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FCGR2C collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting FCGR2C.

ID	Name	Drug Type	Targets	#Targets
DB00002	Cetuximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, EGFR, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......	12
DB00005	Etanercept	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	14
DB00028	Immune Globulin Human	Biotech	C3, C4A, C4B, C5, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR2C, FCGR3A, ......	11
DB00051	Adalimumab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	12
DB00054	Abciximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	14
DB00056	Gemtuzumab ozogamicin	Biotech	C1QA, C1QB, C1QC, C1R, C1S, CD33, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......	12
DB00072	Trastuzumab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, EGFR, ERBB2, FCGR1A, FCGR2A, FCGR2B, F ......	13
DB00073	Rituximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	12
DB00074	Basiliximab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	13
DB00075	Muromonab	Biotech	C1QA, C1QB, C1QC, C1R, C1S, CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2 ......	15
DB00078	Ibritumomab tiuxetan	Biotech	C1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	12
DB00081	Tositumomab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	11
DB00087	Alemtuzumab	Biotech	C1QA, C1QB, C1QC, C1R, CD52, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3 ......	11
DB00092	Alefacept	Biotech	C1QA, C1QB, C1QC, C1R, CD2, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......	11
DB00095	Efalizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	11
DB00108	Natalizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	12
DB00110	Palivizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	10
DB00111	Daclizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	12
DB00112	Bevacizumab	Biotech	C1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......	11

Browse FCGR2C